Invited Speakers: Keynote Speaker:
Progress in Antisense Based Therapeutics
Stanley T. Crooke, D.D., Ph.D., CEO & President
Isis Pharmaceuticals
Program:
Retroviral Vector Antisense Gene Therapy
Gene Targeting by Oligonucleotides
Antisense Oligonucleotides: Delivering the Payload
Triple Helix Based Gene Suppression for Glioblostoma
Anticancer Activity of 2-5A Antisense to Telomerase RNA
Registration :
To Register, visit our website: http://www.ibcusa.com/conf/antisense,
or call for more information or to request a brochure at: 1-508-481-6400.
Deadline for Abstracts: 01/02/98
Email for Requests and Registration: reg@ibcusa.com